

# The Antimicrobial Resistance Patterns & Distribution of Antibiotic Resistance Genes among Carbapenem Resistant *Escherichia coli* Isolated from Diabetic Foot Infection

Huda Zuhair Wahid<sup>1</sup>, Zainab Jaber Hadi<sup>2</sup>, Maryam Fadhil Abd Ela<sup>3</sup>

<sup>1,2,3</sup>Department of Microbiology, Faculty of Medicine, University of Kufa, Iraq.

## Abstract

**Background:** Diabetic foot infection (DFI) is an infection in soft tissue or bone in patient with diabetes mellitus, treatment of DFIs requires appropriate antibiotic selection, continuous updates of the microorganisms that are responsible of infection and their resistance pattern, the aim of this study to determine the frequency of antimicrobial resistance patterns, ESBLs, and MBLs produced carbapenem resistant *Escherichia coli* isolated from patients with DFI.

**Methods:** about 111 swabs specimen were collection from patient suspected with DFI during the period of study, determine the antibiotic susceptibility of *E. coli* isolates by using Kirby-Bauer disk diffusion method to 23 antimicrobial agents. ESBL production was screened by two tests initial method by the disk diffusion method of ceftazidime, ceftriaxone, cefotaxime, and aztreonam (30µg/disk each), according to the CLSI (2021) and confirmatory method by Double disk diffusion test, MBL production by the disk diffusion method of imipenem and meropenem. Molecular detection for ESBL genes by monoplex PCR and MBL genes by multiplex PCR.

**Results:** from 111 swabs specimen *E. coli* isolates had represented in 19 (27.5%) among Gram-negative bacteria. Antibiotic susceptibility test revealed that 10 carbapenem resistant *E. coli* isolates, and the highest resistant to  $\beta$ -lactam class and cephalosporin, results indicated also 100% of isolates were MDR and 63.1 XDR. PCR assay to ESBL genes revealed that *bla*CTX-M was found in 3 (30%) and *bla*OXA was noticed in 4 (40%). The PCR data of MBL genes revealed that the frequency of MBL genes among isolates as following *bla*VIM1 (50%), *bla*NDM2 (100%), and *bla*SIM 2 (100%).

**Conclusion:** the study show high frequency of antibiotic resistant pattern and the presence of ESBL and MBL genes among carbapenem resistant *E. coli* isolated from DFI.

**Keywords:** Diabetic Foot Infection, TEM, SHV.

DOI: 10.47750/pnr.2022.13.S03.160

## INTRODUCTION

Diabetic foot infection (DFI) is an infection in soft tissue or bone for peoples with diabetes, and has grown to be a major reason for non-traumatic amputation<sup>1</sup>. Contamination of bacteria among diabetic foot can cause foot ulceration and this can lead to development gangrene and then amputation, according to some studies about 15-34% of diabetic patients are at risk for developing foot ulcers during their lives<sup>2</sup>. The characterization of *Escherichia coli* isolates from skin and soft tissue infections have been previously published<sup>3,4</sup>. However, this description still poor from DFIs, while *E. coli* is a major pathogenic Gram-negative bacteria isolated from

these ulcers<sup>5,6,7</sup>. Treatment of DFIs requires appropriate antibiotic selection, continuous updates of the microorganisms that are responsible of infection and their resistance pattern<sup>8</sup>. Antibiotic resistance rates vary by country and geographical region<sup>9</sup>. Rising levels of resistance to main antibiotics were initially caused by Extended-Spectrum-Beta-Lactamase (ESBL) producing Gram-negative bacteria in the mid-2000's, and more lately by carbapenemase-producers<sup>10</sup>. The emergence of carbapenem as a therapy for bacteria that are resistant to  $\beta$ -lactamase is a significant advance in clinical practice<sup>11</sup>. Carbapenems have been utilized as a last choice of antibiotics to treat severe infections caused by

Gram-negative bacteria (GNB). However, the therapeutic use of carbapenem is in threat with the development of carbapenemases, mainly metallo- $\beta$ -lactamase (MBL)<sup>12</sup>. Extended spectrum  $\beta$ -lactamases is an enzyme produced by Gram negative bacteria *Enterobacteriaceae*, which can hydrolyze penicillin but also third generation cephalosporin and monobactam and other antibiotics by inactivation of penicillin and cephalosporin by using plasmid-mediated ESBLs such as the TEM, SHV, or CTX-M groups<sup>13</sup>. This study purposed to determine the frequency of antimicrobial resistance patterns for Carbapenem resistant *Escherichia coli* isolated from patients with diabetic foot infection, and investigation the presence of ESBLs and MBL using conventional and multiplex PCR technique.

## MATERIAL AND METHODS

### Sample collection and Identification of Bacteria Isolates

This cross section study was conducted in Al-Sader Medical City in the Najaf province during the period from December 2021 to March 2022. The study population consisted of 111 swabs specimen from patients clinically suspected by the physician to have DFI, and the specimens immediately transported to the microbiology laboratory. All Gram-negative isolates from swab in the current study had been identified by depending on Morphological characteristic, Microscopically examination (gram-stain), and Biochemical tests according to standard method described by MacFaddin and Hart<sup>14 15</sup>. *E. coli* isolates were also identified by the VITEK-2 compact system.

### Antimicrobial Sensitivity Testing

Antimicrobial sensitivity testing of *E. coli* isolates was performed by using disk diffusion methods (Kirby-Baur method). The selection of antibiotic disks (table 1) were performed according to the guidelines recommended by the CLSI. All susceptibility results were interpreted according to the standard values performed by CLSI (2021).

### Phenotypic detection for the Production of (ESBLs) Initial test

All the *E. coli* isolates screened for susceptibility to cefotaxime, ceftazidime and ceftriaxone (30mg/disk each) using disc diffusion sensitivity testing. The isolates were classified as potential ESBL producers if the zone diameter for cefotaxime was  $\leq 26$  mm,  $\leq 21$  mm for ceftazidime and  $\leq 23$  mm for ceftriaxone.

### Confirmatory test using the double disc diffusion test (DDT)

The DDT was carried out by using a standard diffusion assay on Mueller Hinton agar. Disks containing ceftriaxone, cefotaxime, ceftazidime, and aztreonam (30 mg) were placed

at different distances (20–30 mm from center to center, depending on the species) around a disk containing amoxicillin-clavulanic acid (30 mg). Extension of the inhibition zone to the amoxicillin-clavulanic acid disk was indicated suggestive of ESBL production.

### Phenotypic detection for carbapenem resistance

In the present study, carbapenem resistance was defined as resistant to at least one of the two-carbapenem antibiotics tested: imipenem, and meropenem based on the CLSI (2021) guidelines. Isolate that showed as zone of inhibition  $\leq 19$  mm in diameter for imipenem and/or meropenem was considered as carbapenem resistant.

### Molecular Detection of Antimicrobials Resistance Genes

#### ESBLs genes

All carbapenem resistant *E. coli* were screening for detection the presence ESBLs genes by monoplex PCR, the primers sequence and PCR condition illustrated in previous references<sup>16 17 18</sup>. Amplicons were separated by agarose gel electrophoresis in 1.5 % (w/v) agarose gel, stained with ethidium bromide. The positive results were detection when the DNA band base pairs of sample equal to the target product size. The PCR were prepared in total volume 25  $\mu$ l PCR mixture including 12.5  $\mu$ l Promega Master mix, 2  $\mu$ l forward primer (10  $\mu$ M), 2  $\mu$ l reverse primer (10  $\mu$ M), 5  $\mu$ l DNA template (10-250 ng), and 3.5  $\mu$ l nuclease free water, prepared according protocol kit of the manufacturing company (Favorgen). PCR conditions had performed in T3000 thermocycler (Biometra).

#### MBLs genes

All carbapenem resistant *E. coli* were screening for detection the presence MBLs genes by multiplex PCR, the primers sequence and PCR conditions were published elsewhere<sup>19</sup>. Amplicons were separated by agarose gel electrophoresis in 1.5 % (w/v) agarose gel, stained with ethidium bromide. The positive results were detection when the DNA band base pairs of sample equal to the target product size. The PCR were prepared in total volume 50  $\mu$ l PCR mixture including 25  $\mu$ l Promega Master mix, 1.5  $\mu$ l forward primer (10  $\mu$ M), 1.5  $\mu$ l reverse primer (10  $\mu$ M), 2  $\mu$ l DNA template (10-250 ng), and 8  $\mu$ l nuclease free water, prepared according protocol kit of the manufacturing company (Favorgen). PCR conditions had performed in T3000 thermocycler (Biometra).

## RESULTS

The results indicated that out of 111 swabs were cultured, there 93 (83.7%) of specimens were positive for the presence of growth bacterial, while 18 (16.2%) had non growth bacterial. Out of 93 of bacteria isolates were

bacterial growth and the rate of Gram-negative bacteria was 69(74.1%) and 34 (36.5%) was Gram positive bacteria, 19 (27.5%) were identified as *E. coli* based upon colonial characteristics and conventional biochemical tests and VITEK 2 compact system test.

### Antibiotic susceptibility test of *E. coli* isolates

The resistance profile to 23 antibiotics disks belonged to 12 classes of antibiotics as showed in table (1). The highest resistance rate to ampicillin (100%), piperacillin (95%), ceftriaxone (95%),and followed bycefotaxime, cefepime,

cefixime, ciprofloxacin, tetracycline (89.4%),respectively, and followed by tobramycin (84.2%), norfloxacin (84.2%), ceftazidime (79%), Aztreonam (79%), levofloxacin (79%), and nitrofurantoin (79%), respectively. While highest sensitivity of the *E. coli* has been to the colistin (95%), imipenem (63,1%) and amoxicillin-clavulanic acid (63.1%). According to the resistanceprofile (100%) were MDR resistant to at least one antimicrobial for three different categories, and (63.1%) were XDR the isolates were resistant to at least one antibiotic in allbut two or fewer antimicrobial categories.

Table 1: Antibiotics sensitivity test of *E.coli* isolated from patients of DFI (n=19)

Antibiotic class	Antimicrobial agent	No.(%) of isolates exhibited		
		Resistant	Intermediate	Sensitive
Penicillin	Ampicillin	19(100%)	0(0%)	0(0%)
	Piperacillin	18(95%)	1(5.2%)	0(0%)
Beta-lactam	Amoxicillin clavulanate acid	7(37%)	0(0%)	12(63.1%)
	Piperacillin tazobactam	9(47.3%)	5(26.3%)	5(26.3%)
cephems	Ceftazidime	15(79%)	2(10.5%)	2(10.5%)
	Ceftriaxone	18(95%)	0(0%)	1(5.2%)
	Cefotaxime	17(89.4%)	0(0%)	2(10.5%)
	Cefepime	17(89.4%)	0(0%)	2(10.5%)
	Cefixime	17(89.4%)	0(0%)	2(10.5%)
monobactams	Aztreonam	15(79%)	1(5.2%)	3(16%)
carbapenem	Imipenem	6(32%)	1(5.2%)	12(63.1%)
	Meropenem	10(53%)	0(0%)	9(47.3%)
aminoglycosides	Amikacin	10(53%)	0(0%)	9(47.3%)
	Gentamicin	12(63.1%)	0(0%)	7(37%)
	Tobramycin	16(84.2%)	0(0%)	3(16%)
quinolones	Ciprofloxacin	17(89.4%)	1(5.2%)	1(5.2%)
	Levofloxacin	15(79%)	0(0%)	4(21%)
	Norfloxacin	16(84.2%)	0(0%)	3(16%)
Folate pathway	Trimethoprim-Sulphamethazole	13(68.4%)	0(0%)	6(32%)
nitrofurans	Nitrofurantoin	15(79%)	0(0%)	4(21%)
phenicol	Chloramphenicol	10(53%)	1(5.2%)	8(42.1%)
tetracyclines	Tetracycline	17(89.4%)	0(0%)	2(10.5%)
lipopeptides	Colistin	1(5.2%)	0(0%)	18(95%)

### Detection of ESBLs production


The presence of ESBLs was investigated in all *E.coli* isolates using phenotypic tests as follows:

#### Phenotypic screening for the Production of (ESBLs)


The *E.coli*isolates tested by initial screening test, 100% showedresistance to at least one of the third generation cephalosporins (potential ESBLproducers). A positive result was noted with 89.41% for cefotaxime, 95% forceftriaxone, 79% for ceftazidime and aztreonam respectively. All isolates thatexpressed antibiotic resistance to any of the third generation cephalosporinsand aztreonam tested were subjected to confirmatory methods by DDT. However, based on the double disc diffusion test, no isolatewas found to be ESBL producer.

### Molecular Detection and Distribution of ESBLs genes


All 10 carbapenem resistant *E.coli* isolates were screening by conventional PCR for the occurrence of ESBL genes, the result revealed that *blaOXA* was found to be themost prevalent gene among isolates, which are noticed in 4 (40%) isolates Figure (1), followed by *blaCTX-M* that was found in 3 (30%) isolates Figure(2), while *blaTEM* and *blaSHV* were not found in any isolate.



**Figure 1:** Agarose gel electrophoresis of image that show monoplex PCR amplified product from extract DNA of *E.coli* isolates with *blaOXA* genes primers, Lane (1,2,3,4) exhibit positive results with *blaOXA* gene (564 bp). DNA ladder with size\bp (100-1500bp).



**Figure 2:** Agarose gel electrophoresis of image that show monoplex PCR amplified product from extract DNA of *E.coli* isolates with *blaCTX-M* genes primers, Lane (1,2,3) exhibit positive results with *blaCTX-M* gene (554 bp). DNA ladder with size\bp (100-1500bp).



**Figure 3:** Agarose gel electrophoresis of image that show multiplex PCR amplified product from extract DNA of *E.coli* isolates with *blaNDM*, *blaVIM*, *blaIMP*, *blaSIM*, *blaSPM* genes primers, Lane (1) show positive results with *blaNDM* gene (621 bp), *blaSIM* gene (570 bp), and *blaVIM* gene (390 bp). Lane (2) show positive results with *blaNDM* gene (621 bp) and *blaSIM* gene (570 bp). DNA ladder with size\bp (100-1500bp).

### Molecular Detection and Distribution of MBLs genes

All 10 carbapenem resistant *E.coli* isolates were examined by multiplex PCR for the occurrence gene determinants encoding MBL genes (*blaIMP*, *blaVIM*, *blaNDM*, *blaSPM*, and *blaSIM*). The results indicated that presence only two *E.coli* isolate carry the MBL genes (*blaVIM*, *blaNDM*, and *blaSIM*). The frequency of MBL genes among isolates as following *blaVIM*1 (50%), *blaNDM*2 (100%), and *blaSIM* 2 (100%) as shown in figure (3). While *blaSPM* and *blaIMP* were not found in any isolate.

### DISCUSSION

Diabetic foot (DF) is refersto the alterations and abnormalities that occur either separately or together in the feet and legs of diabetic patients<sup>20</sup>.These reasons are less likely to penetrate antimicrobial therapies in DFI, making it more challenging to deliver effective antimicrobial activity to the target location and accelerating the emergence of bacterial resistance<sup>21</sup>. In the current study the prevalence of *E.coli* was 19 (27.5%) among isolates from DFI, similar results have been found previous studies done in Iraq and India with frequency 30% and 25.5% respectively<sup>22,23</sup>. Additionally, other studies conducted in different regions around world with the prevalence of *E.coli* were 19.9%, 14.4%, and 13% done in France, Romanian, and UK respectively <sup>24,25,26</sup>.The other findings the prevalence of *E.coli* was low compared with present study among specimens diabetic foot patients such as study done in Malaysia, Pakistan, and China, which reported 3.8%, 7.2%, and 2.4% respectively <sup>27,28,21</sup>.

The main purpose of this study is to determine the frequency of antimicrobial resistance patterns of *E. coli* isolated from patients with DFI. The results of current study indicated that the highest resistance rate to ampicillin (100%), piperacillin (95%), ceftriaxone (95%), and followed by cefotaxime, cefepime, cefixime, ciprofloxacin, tetracycline (89.4%), respectively, this results are in agreement with previous studies done in Iraq, India, and Ethiopia<sup>29,30,31,32</sup>. While other findings revealed low resistance to this antibiotics such studies conducted in different regions around the world<sup>30,32,33,34</sup>. In contrast the highest sensitivity of the *E. coli* has been to the colistin (95%), imipenem (63.1%) and amoxicillin-clavulanic acid (63.1%), This results are consistent with previous studies performed in South Korea and India that indicated high sensitive to colistin (100%)<sup>35</sup> and another study performed in Iraq found the sensitive to Amoxicillin-clavulanic acid was 82%<sup>33</sup>. The current study demonstrated a high sensitive to imipenem (63.1%), the results is consistent with a study done in Kurdistan Region of Iraq indicated that high sensitive to imipenem 82%<sup>36</sup>. In contrast, a study performed in India revealed that sensitivity rate to imipenem was 33%<sup>37</sup>. In current study, multi resistant isolates to *E. coli* were divided into MDR, XDR and possible PDR according to criterion proposed by Magiorakos *et al.* (2012)<sup>38</sup>. The results indicate that prevalence MDR (100%), XDR (63.1%). Moreover, studies worldwide, including those in Najaf and Egypt which indicated that MDR is the most common among *E. coli* was 83.1% and 93%<sup>39,40</sup>. The MDR isolates are frequent correlated with hospital acquired infections and their extended is associated with raised mortality, morbidity, and healthcare costs. Among other microorganisms, *Enterobacteriales* family indicated the biggest danger because of the presence of ESBLs<sup>41</sup>.

In the present study the prevalence to ESBL genes among carbapenem-resistance *Escherichia coli* isolates, which reported that *blaOXA* was 40% and *blaCTX-M* was 30%, this results similar to study in Nepal carried out on *E. coli* indicated that *blaCTX-M* and *blaOXA* genes were detected in 15% and 37.4% of ESBL isolates, respectively<sup>42</sup>. In contrast another studies performed in Iraq that found ESBL genes among isolates of *Escherichia coli* and indicated high prevalence compared with the present study where reported the prevalence of *blaCTX-M* was 95% and *blaOXA* was 83.6% among isolates of *Escherichia coli*<sup>39</sup>. Besides, many studies in different sites around world indicated that *blaCTX-M* genes more incidence among *E. coli* in clinical isolates such as study done in USA, India, Korea, and Nigeria who reported the prevalence of *blaCTX-M* genes were 16%, 72%, 25%, and 50% respectively<sup>43,44,45,46</sup>.

In this study the occurrence of only two carbapenem-resistance *E. coli* isolates and the percentage of this genes were *blaVIM* 50% and 100% to both *blaNDM* and *blaSIM* respectively, this result similar to result of study conducted in India by Tewari *et al.*, (2022)<sup>47</sup> revealed that occurrence of MBL genes as following *blaVIM* (n=4; 22%), *blaSIM*

(n=4; 22%), and *blaNDM* (n=2; 11%) among *E. coli* isolates. In contrast, the other finding in Pakistan who reported the high occurrence of *blaVIM* (n= 30; 25%) and *blaNDM* (n=43; 36%)<sup>34</sup>.

## CONCLUSIONS

In this study revealed the high frequency to antimicrobial resistant pattern among *E. coli* isolates from patients with DFI, the results showed that 100% of isolates were MDR, and the results also indicated that the highest resistance rate toward beta-lactam class and the generation of cephalosporin, while highest sensitivity of the *E. coli* has been to the colistin and imipenem, and also there is the presence of MBL genes (*blaVIM*, *blaNDM*, and *blaSIM*) and ESBL genes (*blaOXA* and *blaCTX*) among carbapenem resistant *E. coli* isolates.

## REFERENCES

- Shahbay A, Horumpende P, Shahbay Z, et al. Clinical profiles of diabetic foot ulcer patients undergoing major limb amputation at a tertiary care center in North-eastern Tanzania. *BMC Surg.* 2021;21(1):1-7.
- Armstrong DG, Swerdlow MA, Armstrong AA, Conte MS, Padula W V, Bus SA. Five year mortality and direct costs of care for people with diabetic foot complications are comparable to cancer. *J Foot Ankle Res.* 2020;13(1):1-4.
- Petkovšek Z, Eleršič K, Gubina M, Zgur-Bertok D, Starčič Erjavec M. Virulence potential of *Escherichia coli* isolates from skin and soft tissue infections. *J Clin Microbiol.* 2009;47(6):1811-1817.
- Ranjan A, Shaik S, Nandanwar N, et al. Comparative genomics of *Escherichia coli* isolated from skin and soft tissue and other extraintestinal infections. *MBio.* 2017;8(4):e01070-17.
- Jain SK, Barman R. Bacteriological profile of diabetic foot ulcer with special reference to drug-resistant strains in a tertiary care center in North-East India. *Indian J Endocrinol Metab.* 2017;21(5):688.
- Li X, Qi X, Yuan G, et al. Microbiological profile and clinical characteristics of diabetic foot infection in northern China: a retrospective multicentre survey in the Beijing area. *J Med Microbiol.* 2018;67(2):160-168.
- Miyani Z, Fawwad A, Sabir R, Basit A. Microbiological pattern of diabetic foot infections at a tertiary care center in a developing country. *Age Years.* 2017;53:10-20.
- Pitocco D, Spanu T, Di Leo M, et al. Diabetic foot infections: A comprehensive overview. *Eur Rev Med Pharmacol Sci.* 2019;23(2):26-37. doi:10.26355/EURREV\_201904\_17471
- Sebastian S, Tom AA, Babu JA, Joshy M. Antibiotic resistance in *Escherichia coli* isolates from poultry environment and UTI patients in Kerala, India: A comparison study. *Comp Immunol Microbiol Infect Dis.* 2021;75:101614.
- Al-Abdely H, AlHababi R, Dada HM, et al. Molecular characterization of carbapenem-resistant *Enterobacteriales* in thirteen tertiary care hospitals in Saudi Arabia. *Ann Saudi Med.* 2021;41(2):63-70. doi:10.5144/0256-4947.2021.63
- Hemalatha V, Sekar U, Kamat V. Detection of metallo beta-lactamase producing *Pseudomonas aeruginosa* in hospitalized patients. *Indian J Med Res.* 2005;122(2):148.
- Ranjan S, Banashankari GS, Babu PRS. Evaluation of phenotypic tests and screening markers for detection of metallo-β-lactamases in clinical isolates of *Pseudomonas aeruginosa*: A prospective study. *Med J Dr DY Patil Univ.* 2015;8(5):599.
- Kristianingtyas L, Effendi MH, Tyasningsih W, Kurniawan F. Genetic identification of *blaCTX-M* gene and *blaTEM* gene on extended

- spectrum beta lactamase (ESBL) producing *Escherichia Coli* from Dogs. *Indian Vet J.* 2020;97(1):17-21.
- MacFaddin JF. *Biochemical Tests for Identification of Bacteria of Medical Importance.* Published online 2000.
- Hart CA. *Klebsiella, citrobacter, enterobacter and serratia spp.* *Princ Pract Clin Bacteriol.* Published online 2006:377-386.
- Rasheed JK, Jay C, Metchock B, et al. Evolution of extended-spectrum beta-lactam resistance (SHV-8) in a strain of *Escherichia coli* during multiple episodes of bacteremia. *Antimicrob Agents Chemother.* 1997;41(3):647-653.
- Saladin M, Cao VTB, Lambert T, et al. Diversity of CTX-M  $\beta$ -lactamases and their promoter regions from Enterobacteriaceae isolated in three Parisian hospitals. *FEMS Microbiol Lett.* 2002;209(2):161-168. doi:10.1016/S0378-1097(02)00484-6
- Dallenne C, Da Costa A, Decré D, Favier C, Arlet G. Development of a set of multiplex PCR assays for the detection of genes encoding important  $\beta$ -lactamases in Enterobacteriaceae. *J Antimicrob Chemother.* 2010;65(3):490-495.
- Poirel L, Walsh TR, Cuvillier V, Nordmann P. Multiplex PCR for detection of acquired carbapenemase genes. *Diagn Microbiol Infect Dis.* 2011;70(1):119-123.
- Braun S, Silva M. Clinical and microbiological characteristics of diabetic foot infection by carbapenem-resistant bacteria in a hospital in southern Brazil. *Evidência.* Published online 2021:1-10. doi:10.18593/eba.27178
- Li X, Du Z, Tang Z, Wen Q, Cheng Q, Cui Y. Distribution and drug sensitivity of pathogenic bacteria in diabetic foot ulcer patients with necrotizing fasciitis at a diabetic foot center in China. *BMC Infect Dis.* 2022;22(1):1-10. doi:10.1186/s12879-022-07382-7
- Lukey NM, Abbas FM. Genotypic detection of GES and VEB extended spectrum  $\beta$ -lactamase among aerobic Gram-negative bacteria isolated from diabetic foot ulcers. *IOP Conf Ser Earth Environ Sci.* 2021;790(1). doi:10.1088/1755-1315/790/1/012054
- Datta P, Chander J, Gupta V, Mohi GK, Attri AK. Evaluation of various risk factors associated with multidrug-resistant organisms isolated from diabetic foot ulcer patients. *J Lab Physicians.* 2019;11(01):58-62.
- Lienard A, Hosny M, Jneid J, et al. *Escherichia coli* isolated from diabetic foot osteomyelitis: Clonal diversity, resistance profile, virulence potential, and genome adaptation. *Microorganisms.* 2021;9(2):1-17. doi:10.3390/microorganisms9020380
- Uivaraseanu B, Bungau S, Tit DM, et al. Clinical, pathological and microbiological evaluation of diabetic foot syndrome. *Med.* 2020;56(8):1-13. doi:10.3390/medicina56080380
- Arias M, Hassan-Reshat S, Newsholme W. Retrospective analysis of diabetic foot osteomyelitis management and outcome at a tertiary care hospital in the UK. *PLoS One.* 2019;14(5):1-16. doi:10.1371/journal.pone.0216701
- Sharifah Aisyah SH, Siti Asma' H, Nurahan M. The significant association between polymicrobial diabetic foot infection and its severity and outcomes. *Malaysian J Med Sci.* 2019;26(1):107-114. doi:10.21315/mjms2019.26.1.10
- Asghar M, Haq M, Ahmad A, et al. Molecular Identification Of Different Gram Positive And Gram Negative Bacteria From Diabetic Foot Patients In Khyber Teaching Hospital ( KTH ) Peshawar KP Pakistan. 2022;9(1):1159-1167.
- Albadri ATJ. Characterization and Molecular study to detect Multidrug Resistance Bacteria Isolated from Patients with Diabetic Foot Ulcers in Wasit Province. 2021;(September):2-142. doi:10.13140/RG.2.2.12971.57121
- Salman HA, Alhameedawi AK, Alsallameh SMS, Muhamad G, Taha Z. Prevalence of Multi-Antibiotic Resistant Bacteria Isolated from Children with Urinary Tract Infection from Baghdad, Iraq. *Microbiol Biotechnol Lett.* 2022;50(1):147-156. doi:10.48022/mb1.2110.10011
- Saseedharan S, Sahu M, Chaddha R, et al. Epidemiology of diabetic foot infections in a reference tertiary hospital in India. *Brazilian J Microbiol.* 2018;49(2):401-406. doi:10.1016/j.bjm.2017.09.003
- Woldemariam HK, Geleta DA, Tulu KD, et al. Common uropathogens and their antibiotic susceptibility pattern among diabetic patients. *BMC Infect Dis.* 2019;19(1):1-10. doi:10.1186/s12879-018-3669-5
- Dawood WS. Molecular and susceptibility study of antibiotic resistance genes in *E. Coli* isolated from selected iraqi patients. *Syst Rev Pharm.* 2020;11(9):214-223. doi:10.31838/srp.2020.9.35
- Bilal H, Rehman TU, Khan MA, et al. bla NDM-1 Harboring Clinically Isolated *Escherichia coli* from Pakistan. Published online 2021:1467-1479.
- Park Y, Choi Q, Kwon GC, Koo SH. Emergence and transmission of New Delhi metallo-beta-lactamase-5-producing *Escherichia coli* Sequence Type 361 in a Tertiary Hospital in South Korea. *J Clin Lab Anal.* 2020;34(2):1-8. doi:10.1002/jcla.23041
- Ahmed HJ, Ganjo AR. Detection of Carbapenemase-Producing *Klebsiella pneumoniae* and *Escherichia coli* Recovered from Clinical Specimens in Erbil City Kurdistan Region of Iraq. *Al-Mustansiriyah J Sci.* 2019;30(2):10-18. doi:10.23851/mjs.v30i2.612
- Sharma B, Sharma R, Pal N, Vyas L. Microbiological profile and antibiotic sensitivity pattern of burn wound infection in an Indian Tertiary Care Hospital. *J Pure Appl Microbiol.* 2011;5(2):837-841.
- Magiorakos A-P, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. *Clin Microbiol Infect.* 2012;18(3):268-281.
- Al-Shammari NAHH. Prevalence of Integrons and Insertion Sequences in Extended-Spectrum  $\beta$  -lactamases (ESBL)- Producing *Escherichia coli* Isolated from Patients with Urinary Tract Infections in Najaf Province. 2021;(M.Sc. Thesis. College of Medicen. Kufa University.).
- El-baz R, Said HS, Abdelmegeed ES, Barwa R. Characterization of virulence determinants and phylogenetic background of multiple and extensively drug resistant *Escherichia coli* isolated from different clinical sources in Egypt. *Appl Microbiol Biotechnol.* 2022;106(3):1279-1298. doi:10.1007/s00253-021-11740-x
- Malik S, Sidhu PK, Rana JS, Nehra K. Managing urinary tract infections through phage therapy: a novel approach. *Folia Microbiol (Praha).* 2020;65(2):217-231.
- Manandhar S, Zellweger RM, Maharjan N, et al. A high prevalence of multi-drug resistant Gram-negative bacilli in a Nepali tertiary care hospital and associated widespread distribution of Extended-Spectrum Beta-Lactamase (ESBL) and carbapenemase-encoding genes. *Ann Clin Microbiol Antimicrob.* 2020;19(1):1-13. doi:10.1186/s12941-020-00390-y
- Tamma PD, Smith TT, Adebayo A, et al. Prevalence of blaCTX-M genes in gram-negative bloodstream isolates across 66 hospitals in the United States. *J Clin Microbiol.* 2021;59(6):1-8. doi:10.1128/JCM.00127-21
- Sivaraman GK, Rajan V, Vijayan A, Elangovan R, Prendiville A, Bachmann TT. Antibiotic Resistance Profiles and Molecular Characteristics of Extended-Spectrum Beta-Lactamase (ESBL)-Producing *Escherichia coli* and *Klebsiella pneumoniae* Isolated From Shrimp Aquaculture Farms in Kerala, India. *Front Microbiol.* 2021;12(August):1-13. doi:10.3389/fmicb.2021.622891
- Rajivgandhi G, Maruthupandy M, Ramachandran G, Priyanga M, Manoharan N. Detection of ESBL genes from ciprofloxacin resistant Gram negative bacteria isolated from urinary tract infections (UTIs). *Front Lab Med.* 2018;2(1):5-13. doi:10.1016/j.flm.2018.01.001
- Adeyemo AT, Kolawole B, Rotimi VO, Aboderin AO. Multicentre study of the burden of multidrug-resistant bacteria in the aetiology of infected diabetic foot ulcers. *Afr J Lab Med.* 2021;10(1):1-10. doi:10.4102/AJLM.V10I1.1261
- Tewari R, Ganaie F, Venugopal N, Mitra S, Shome R, Shome BR. Occurrence and characterization of genetic determinants of  $\beta$ -lactamase resistance in *Escherichia coli* clinical isolates. *Infect Genet Evol.* 2022;100(August 2021):105257. doi:10.1016/j.meegid.2022.105257